Journal
EXPERIMENTAL AND MOLECULAR PATHOLOGY
Volume 78, Issue 3, Pages 257-262Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yexmp.2005.01.001
Keywords
Sabaeksan; asthma; human mast cell line HMC-1; TNF-alpha; IL-6; IL-8; NF-kappa B
Categories
Ask authors/readers for more resources
Sabaeksan has been used for prevention and treatment of bronchial asthma and allergic asthma in Korea. To investigate the biological effect of Sabaeksan, we examined the effect of Sabaeksan on the phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187-induced pro-inflammatory cytokines secretion in human mast cell line HMC-1 cells. Sabaeksan by itself had no effect on viability of HMC-1 cells. The effects of Sabaeksan on the secretion of tumor necrosis factor (TNF)-alpha, interleukin (lL)-6, and IL-8 from HMC-1 were evaluated with enzyme-linked immumosorbent assay. Sabaeksan (1 mg/ml) inhibited PMA plus A23187-induced TNF-alpha, IL-6, and IL-8 secretion by 43.86 +/- 5.26%, 56.39 +/- 3.65%, and 63.48 +/- 2.54%, respectively. Sabaeksan also inhibited the nuclear factor-kappa B (NF-kappa B) activation and I kappa B alpha degradation. Taken together, these results suggest that Sabaeksan inhibits the secretion of pro-inflammatory cytokines in HMC-1 cells through blockade of NF-kappa B activation. (c) 2005 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available